AK 001

Drug Profile

AK 001

Alternative Names: AK001

Latest Information Update: 05 Dec 2016

Price : $50

At a glance

  • Originator Johns Hopkins University School of Medicine
  • Developer Allakos
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Antibodies; Skin disorder therapies
  • Mechanism of Action Immunomodulators; Mast cell inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Nasal polyps
  • Phase I Hypersensitivity

Most Recent Events

  • 29 Nov 2016 Allakos in-licenses Siglec-8 receptor intellectual property from The Johns Hopkins University School of Medicine
  • 08 Sep 2016 Phase-II clinical trials in Nasal polyps (Combination therapy) in USA (Parenteral) (NCT02734849)
  • 01 Mar 2016 Allakos completes a phase I trial in Hypersensitivity in USA (NCT02563938)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top